참고문헌
- Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053. https://doi.org/10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2
- Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237-249. https://doi.org/10.1093/aje/kwn121
- Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049-1057. https://doi.org/10.1093/jnci/djr203 Erratum in: J Natl Cancer Inst 2013;105:581.
- Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol 2022;117:559-587. https://doi.org/10.14309/ajg.0000000000001680
- Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol 2013;108:915-922. https://doi.org/10.1038/ajg.2013.72
- Pandeya N, Webb PM, Sadeghi S, Green AC, Whiteman DC. Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut 2010;59:31-38. https://doi.org/10.1136/gut.2009.190827
- Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-1677. https://doi.org/10.1053/j.gastro.2003.09.030
- Ward EM, Wolfsen HC, Achem SR, et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006;101:12-17. https://doi.org/10.1111/j.1572-0241.2006.00379.x
- Nguyen TH, Thrift AP, Rugge M, El-Serag HB. Prevalence of Barrett's esophagus and performance of societal screening guidelines in an unreferred primary care population of U.S. veterans. Gastrointest Endosc 2021;93:409-419.e1. https://doi.org/10.1016/j.gie.2020.06.032
- Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010;105:1490-1502. https://doi.org/10.1038/ajg.2010.2
- Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:1046-1055.e8. https://doi.org/10.1016/j.cgh.2017.11.044
- Moe GL, Kristal AR, Levine DS, Vaughan TL, Reid BJ. Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer 2000;36:7-13. https://doi.org/10.1207/S15327914NC3601_2
- Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997;89:1277-1284. https://doi.org/10.1093/jnci/89.17.1277
- Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999;94:3420-3426. https://doi.org/10.1111/j.1572-0241.1999.01603.x
- Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol 2004;99:1657-1666. https://doi.org/10.1111/j.1572-0241.2004.30426.x
- O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-2042. https://doi.org/10.1111/j.1572-0241.1999.01275.x
- Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-620. https://doi.org/10.7326/0003-4819-132-8-200004180-00003
- Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:220-227; quiz e26. https://doi.org/10.1016/j.cgh.2010.11.008
- Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002;97:1930-1936. https://doi.org/10.1111/j.1572-0241.2002.05902.x
- Gaddam S, Singh M, Balasubramanian G, et al. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology 2013;145:548-553.e1. https://doi.org/10.1053/j.gastro.2013.05.040
- Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831. https://doi.org/10.1056/NEJM199903183401101
- Cook MB, Corley DA, Murray LJ, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). PLoS One 2014;9:e103508. https://doi.org/10.1371/journal.pone.0103508
- Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut 2014;63:1229-1237. https://doi.org/10.1136/gutjnl-2013-305997
- Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2013;11:382-388. https://doi.org/10.1016/j.cgh.2012.11.014
- Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a systematic review and meta-analysis. PLoS One 2017;12:e0169691. https://doi.org/10.1371/journal.pone.0169691
- Spechler SJ, Sharma P, Traxler B, Levine D, Falk GW. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 2006;101:1964-1971. https://doi.org/10.1111/j.1572-0241.2006.00661.x
- Wani S, Sampliner RE, Weston AP, et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. Aliment Pharmacol Ther 2005;22:627-633. https://doi.org/10.1111/j.1365-2036.2005.02626.x
- Jo HJ, Lee HS, Kim N, et al. Predictable marker for regression of Barrett's esophagus by proton pump inhibitor treatment in Korea. J Neurogastroenterol Motil 2013;19:210-218. https://doi.org/10.5056/jnm.2013.19.2.210
- Chang EY, Morris CD, Seltman AK, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review. Ann Surg 2007;246:11-21. https://doi.org/10.1097/01.sla.0000261459.10565.e9